ライフサイエンスコーパス: antiplatelet drug

1 associated with combined use of a VKA and an antiplatelet drug.

2 nt brain ischaemia more effectively than are antiplatelet drugs.

3 have emerged, establishing a need for novel antiplatelet drugs.

4 A) alleles showed increased sensitivity to 2 antiplatelet drugs.

5 standard heparin may potentiate efficacy of antiplatelet drugs.

6 nticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs.

7 for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge completely eliminated

8 A new antiplatelet drug and a number of trials involving HMG C

9 telets are less responsive to the effects of antiplatelet drugs and contain messenger ribonucleic aci

10 use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute s

11 junctive therapies, such as corticosteroids, antiplatelet drugs and other immunosuppressive agents of

12 re, thrombolytics during, and beta-blockers, antiplatelet drugs, and angiotensin-converting-enzyme (A

13 the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologi

14 prised prescription fills for beta-blockers, antiplatelet drugs, angiotensin-converting enzyme inhibi

15 Concomitant antiplatelet drugs appeared to increase the risk for maj

16 schemic agents (nitrates and beta blockers), antiplatelet drugs (aspirin, P2Y(12), and glycoprotein I

17 l individual pharmacological agents, such as antiplatelet drugs, beta-blockers, ACE inhibitors, and l

18 inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-blockers, and statins on all-ca

19 port the inhibition of GPR17 by the marketed antiplatelet drugs cangrelor and ticagrelor, previously

20 The antiplatelet drug clopidogrel is a new thienopyridine de

21 nistration of FXI ASO with enoxaparin or the antiplatelet drug clopidogrel produced improved antithro

22 standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.

23 , structures of 2B4 were determined with the antiplatelet drugs clopidogrel and ticlopidine, which we

24 acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate t

25 Moreover, the effect is unresponsive to antiplatelet drugs commonly used.

26 -two (10.6%) patients interrupted at least 1 antiplatelet drug during the first year after DES implan

27 Measurement of antiplatelet drug efficacy with a point-of-care device a

28 The biological response to antiplatelet drugs has repeatedly been shown to predict

29 el was compatible with reduced mortality for antiplatelet drugs (hazard ratio [HR], 0.86; 95% CI, 0.7

30 Y12 inhibitors are among the most successful antiplatelet drugs, however, show remarkable variability

31 This study supports that antiplatelet drugs improve survival and beta-blockers de

32 with a previous ICH treated with warfarin or antiplatelet drugs in comparison with no antithrombotic

33 The relative safety and efficacy of some antiplatelet drugs in women has been disputed.

34 Currently used antiplatelet drugs, including aspirin and ticlopidine, a

35 A number of new antiplatelet drugs, including clopidogrel and the glycop

36 ements in surgical technique; more effective antiplatelet drugs; increasingly intensive risk factor m

37 e diphosphate receptor P2Y12, the target for antiplatelet drugs like clopidogrel, facilitates delayed

38 est when a VKA was used concurrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of c

39 troke, or myocardial infarction treated with antiplatelet drugs (mainly aspirin based, without routin

40 quences in influenza virus pathogenesis, and antiplatelet drugs might be explored to develop new anti

41 , the method was applied to the synthesis of antiplatelet drug n-butyl phthalide and cytotoxic agonis

42 esent treatment is based on a combination of antiplatelet drugs, optimisation of blood pressure and L

43 mportant for patients who take warfarin with antiplatelet drugs or nonselective nonsteroidal anti-inf

44 ctive effect for warfarin patients not using antiplatelet drugs or NSAIDs (HR, 0.86; 95% CI, 0.70-1.0

45 Among patients concurrently using antiplatelet drugs or NSAIDs, those without PPI co-thera

46 t reduction occurred in patients also taking antiplatelet drugs or NSAIDs.

47 The findings suggest applications of antiplatelet drugs or TP receptor antagonists for the tr

48 Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its opt

49 ment options now include the next-generation antiplatelet drugs prasugrel and ticagrelor, and, in ter

50 Antiplatelet drugs provide first-line antithrombotic the

51 diovascular outpatients participating in the Antiplatelet Drug Resistances and Ischemic Events (ADRIE

52 hough the gold standard definition to assess antiplatelet drug response has not been fully establishe

53 Biological antiplatelet drug responsiveness, measured with specific

54 lishment of a PFT therapeutic range for each antiplatelet drug should be considered and is discussed.

55 ngiotensin-converting enzyme inhibition, and antiplatelet drugs significantly reduce the risk of card

56 was defined as the combination of at least 1 antiplatelet drug, statin, beta-blocker, and angiotensin

57 cal trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at

58 e us in appropriate use of antithrombotic or antiplatelet drug therapy to decrease the risk of events

59 ond 6 months, possibly because of inadequate antiplatelet drug therapy.

60 The effect of adding other antiplatelet drugs to aspirin for long-term secondary pr

61 Among patients in whom antiplatelet drug use was discontinued at least 2 days b

62 yridine administration and with inconsistent antiplatelet drug use within 30 days.

63 isk patients, taking both anticoagulants and antiplatelet drugs when topical anesthesia is administer

64 domized trials to guide perioperative use of antiplatelet drugs, which affect the risk of both bleedi

65 oring of platelet function and the effect of antiplatelet drugs will improve outcomes in cardiovascul